<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110903</url>
  </required_header>
  <id_info>
    <org_study_id>20020378</org_study_id>
    <nct_id>NCT00110903</nct_id>
  </id_info>
  <brief_title>Treatment for Subjects With Active Rheumatoid Arthritis (RA)</brief_title>
  <official_title>Open-Label Study to Assess the Safety of Etanercept Liquid Administered Once Weekly in Subjects With Active Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of etanercept liquid administered once
      weekly to subjects with RA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects having positive immunoassay response to etanercept liquid during the treatment period.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, infectious episodes, serious adverse events, serious infectious episodes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements from safety laboratory assessments.</measure>
  </secondary_outcome>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept Liquid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Fulfill the 1987 American Rheumatism Association (ARA) criteria for
        RA - Active RA at the time of enrollment, receipt of concomitant methotrexate at a dose of
        up to 25 mg a week is permitted - Screening lab results must demonstrate:

          -  AST and ALT less than or equal to 2 times the upper limit of normal hemoglobin greater
             than or equal to 8.5 g/dL;

          -  Platelet count greater than or equal to 125,000/cm3;

          -  White blood cell count (WBC) greater than or equal to 3500 cells/cm3;

          -  Serum creatinine less than or equal to 2 mg/dL - Before any study specific procedure
             is performed, the subject must provide informed consent for participation in the study
             Exclusion Criteria: - Previous receipt of etanercept - Receipt of antibody to (tumor
             necrosis factor) TNF alpha or other TNF inhibitors within 90 days of Day 1 - Currently
             enrolled in other investigational device or drug trials, or participation in
             investigational trial within the past 30 days - Receipt of intra-articular
             corticosteroids within 14 days prior to Day 1 - Receipt of any disease-modifying
             anti-rheumatic drugs (DMARDs) within 28 days of Day 1 - Receipt of cyclophosphamide
             within 6 months of Day 1 - Concomitant corticosteroids greater than 10 mg/day of
             prednisone (or equivalent) during 14 days prior to Day 1 - Dose of nonsteroidal
             anti-inflammatory drug (NSAID) must be stable for 14 days prior to Day 1 and must not
             exceed the recommended dose in the product information sheet - Subject is not using
             adequate contraception - Subject is pregnant or breast-feeding - Subject has
             significant concurrent medical disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007 Jan-Feb;25(1):40-6.</citation>
    <PMID>17417989</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2005</study_first_submitted>
  <study_first_submitted_qc>May 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2005</study_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>etanercept</keyword>
  <keyword>Immunex</keyword>
  <keyword>Amgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

